Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

The latest update on Tuesday morning shows Alnylam Pharmaceuticals shares up by 3.84%, trading at $472.0. At this price, ...

Six companies, including Alnylam Pharmaceuticals and Seagate Technology, will join the Nasdaq 100 when the changes take effect later this month. The updates aim to keep the index aligned with the ...

Alnylam Pharmaceuticals ( ALNY) said it reached privately negotiated agreements to repurchase for cash about $34.4M of its 1.00% Convertible Senior Notes due 2027. The company will pay roughly $51.9M ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...

Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran. The U.S. FDA has slapped a three-month delay on its review of the RNA interference (RNAi) ...

An Alnylam Pharmaceuticals drug that treats nerve pain caused by an inherited protein disorder now has results from a pivotal clinical trial showing the drug also helps patients suffering the ...

The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed ...

Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ...